Switzerland’s Sandoz pivots to biosimilars, expects rapid mid-term growth
ZURICH, Sept 8 (Reuters) – Sandoz aims to more than double net sales from 2025 to 2035, the Swiss drug maker said on Tuesday at its capital markets day, where it outlined its new Bio100 biosimilars strategy, pivoting its focus from generics to biosimilars. “Our Bio100 ambitions are set to position biosimilars to become the majority of our sales,” Sandoz’s Chief Executive Richard Saynor said in a statement. Sandoz said it is also […]